Results 141 to 150 of about 77,746 (246)

TGFβ1 Activates Lnc‐APUE to Promote Tumor Metastasis via the Alu Element‐Driven STAU1‐Mediated Decay of CDH1 mRNA

open access: yesAdvanced Science, EarlyView.
We delineate a TGFβ1/SMAD/lnc‐APUE/E‐cadherin axis wherein TGFβ1 signaling activates lnc‐APUE; lnc‐APUE subsequently downregulates E‐cadherin expression via Alu element‐driven STAU1‐mediated decay of CDH1 mRNA, thereby promoting tumor metastasis. Our findings reveal a novel regulatory function for lnc‐APUE within the SMD pathway, elucidate a distinct ...
Song‐Yang Li   +10 more
wiley   +1 more source

Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives. [PDF]

open access: yesNeurol Ther
Freedman MS   +10 more
europepmc   +1 more source

Adipocyte‐Derived Exosomal miR‐5099 Mitigates M1 Macrophage Polarization and Adipose Inflammation via c‐Met/NF‐κB Axis to Improve Metabolic Health

open access: yesAdvanced Science, EarlyView.
Celastrol upregulates adipocyte‐derived exosomal miR‐5099, suppressing the macrophage c‐Met/NF‐κB axis to mitigate pro‐inflammatory M1 polarization and adipose inflammation. These miR‐5099‐enriched exosomes also act as endocrine signals targeting the liver, muscle, and adipocytes to significantly enhance systemic insulin sensitivity.
Ping Tang   +9 more
wiley   +1 more source

Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next‐Generation Approaches

open access: yesAdvanced Science, EarlyView.
This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey   +6 more
wiley   +1 more source

Targeting PRKCN, an Essential Driver Orchestrating mTOR‐IRF4 Axis Independently of Kinase Activity, in Multiple Myeloma

open access: yesAdvanced Science, EarlyView.
Constitutive PRKCN expression is driven by super‐enhancers and modulated by NF‐κB signaling in multiple myeloma (MM). PRKCN activates mTORC1/2‐IRF4 signaling axis and favors tumor cell growth independently of its kinase activity. IRF4 reciprocally promotes PRKCN transcription, creating a feed‐forward loop.
Koukou Tang   +12 more
wiley   +1 more source

Biomimetic Iridium‐Based Photothermal Nanozyme to Trigger Ferroptosis and Pyroptosis and Activate the cGAS‐STING Pathway for Improved Tumor Immunotherapy

open access: yesAdvanced Science, EarlyView.
This study develops an iridium‐based nanozyme (IIN@M) with superior enzyme‐like activity and photothermal performance. It disrupts intracellular redox balance by generating reactive oxygen species and depleting glutathione, which synergistically induces ferroptosis, pyroptosis, and immunogenic cell death.
Lijun Ding   +7 more
wiley   +1 more source

Engineering MnPt Bimetallic Nanozymes for Cascade Enzymatic Therapy and Enhanced Radio‐Immunotherapy

open access: yesAdvanced Science, EarlyView.
A CD44‐targeted MnPt bimetallic nanozyme (HD@MnO2) integrates multienzyme‐like activity with cGAS–STING activation to boost radio‐immunotherapy. Through cascade biocatalysis, it depletes glutathione, relieves hypoxia, and amplifies ROS, enhancing radiotherapy‐induced DNA damage and immunogenic cell death. The nanozyme promotes dendritic cell maturation
Wenyi Zhang   +8 more
wiley   +1 more source

Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial. [PDF]

open access: yesInt Immunopharmacol, 2020
Dastan F   +11 more
europepmc   +1 more source

Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. [PDF]

open access: yesLancet Respir Med, 2021
Monk PD   +13 more
europepmc   +1 more source

CD3ɛ Nanobody‐Engineered Extracellular Vesicles Driving In Vivo Generation of TCE‐secreting CAR‐Ts for Solid Tumor Therapy With Memory Response and Minimal Immunogenicity

open access: yesAdvanced Science, EarlyView.
HEK‐293T‐derived CD3ε Nb‐engineered EVs to generate dual‐targeting CAR‐T cells directly in vivo. These EVs selectively deliver CAR.BiTE transgenes into T cells and reprogramed to HLA‐G/PD‐L1‐targeting effector cells with enhanced memory and persistence.
Shi‐Wei Huang   +27 more
wiley   +1 more source

Home - About - Disclaimer - Privacy